Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for entities : Incyte corporation save search
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.17%
H: 1.41%
C: -0.22%
t-cell for therapy growth market
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: -0.58%
license collaboration asia agreement
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: -0.58%
license collaboration asia agreement china
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.49%
H: 0.84%
C: -0.07%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.09%
H: 1.42%
C: 1.1%
ibi310 first cancer colon therapy study
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 06:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.4%
H: 0.38%
C: -1.77%
lung cancer treatment therapeutics china
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.6%
H: 0.45%
C: 0.08%
MRUS | $40.41 -1.56% -1.58% 240K
|
Health Technology
|
| O: 2.3%
H: 0.58%
C: -2.69%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -3.07%
business year update financial results
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Published: 2024-02-27 (Crawled : 23:00) - biospace.com/
SNDX | $20.44 -1.45% -1.47% 1.2M
|
Health Technology
|
| O: 0.88%
H: 1.12%
C: -0.73%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.2%
H: 1.37%
C: 0.58%
drug disease review food treatment grants
Anju Software Unveils Strategies for Data-Driven Decision-Making in Clinical Research at SCOPE Orlando 2024
Published: 2024-02-08 (Crawled : 16:00) - prnewswire.com
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.02%
H: 0.65%
C: 0.02%
software research
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
Published: 2024-02-07 (Crawled : 09:00) - prnewswire.com
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.65%
H: 0.57%
C: -3.21%
first management drug application china
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -1.32%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.08%
H: 0.81%
C: -0.19%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.52%
H: 0.72%
C: -0.34%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.35%
H: 1.07%
C: -0.27%
candidate tumors collaboration trial advanced china therapy
THE SKIN OF COLOR SOCIETY (SOCS) REPORTS A BANNER YEAR OF PROGRESS TOWARD GREATER DIVERSITY & INCLUSION IN DERMATOLOGY AND HEALTH EQUITY FOR PATIENTS OF COLOR
Published: 2023-12-27 (Crawled : 15:30) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.36%
H: 0.03%
C: 0.03%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.39%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.2%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.18%
H: 0.56%
C: 0.38%
health year skin
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension
Published: 2023-12-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.36%
H: 0.03%
C: 0.03%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.2%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.18%
H: 0.56%
C: 0.38%
drug sirna treatment collaboration hypertension
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Published: 2023-12-06 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -2.77%
H: 0.49%
C: 0.49%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.2%
H: 1.7%
C: 1.3%
rient-16 treatment results study
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
Published: 2023-11-24 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.69%
H: 1.66%
C: 1.66%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.46%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.34%
H: 0.37%
C: 0.3%
ibi351 drug granted review designation medical application china
AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
Published: 2023-11-22 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.56%
H: 1.06%
C: -0.24%
drug application therapeutics
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)
Published: 2023-11-22 (Crawled : 13:30) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.56%
H: 1.06%
C: -0.24%
drug medical application therapeutics china
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
MRUS | $40.41 -1.56% -1.58% 240K
|
Health Technology
|
| O: 3.51%
H: 9.56%
C: 9.56%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.52%
H: 1.38%
C: 1.11%
business update financial results
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
Published: 2023-10-13 (Crawled : 23:00) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.27%
H: 2.14%
C: 2.11%
opzelura children dermatitis
Innovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration
Published: 2023-10-09 (Crawled : 00:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.77%
H: 0.21%
C: -0.37%
ibi302 macular treatment protein study
Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
Published: 2023-09-29 (Crawled : 00:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.64%
H: 0.04%
C: -0.57%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: -1.85%
fucaso car-t
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.